Rachel Haurwitz, Ph.D.
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Barbara McClung, J.D.
Barbara serves as Chief Legal Officer and Corporate Secretary for Caribou Biosciences, where she is responsible for all legal functions, including intellectual property strategy and portfolio management, contracts, corporate transactions, board governance, and employment law. In addition, the Company's finance and human resources functions report to Barbara. Prior to joining Caribou, she headed the legal functions at Intarcia Therapeutics, Inc. and Cygnus, Inc. Barbara began her career as a patent attorney with E. I. du Pont de Nemours and Company, and then joined Chiron Corporation where she was patent counsel for Chiron’s vaccine division. Barbara is a member of the California, Delaware and Pennsylvania bars, as well as being a registered patent attorney before the United States Patent and Trademark Office. Barbara received her B.A. from the University of California, San Diego, and her J.D. from the University of Pennsylvania Law School.
Steven Kanner, Ph.D.
Steve is the Chief Scientific Officer of Caribou Biosciences responsible for all R&D activities and operations. Before joining Caribou in June of 2017, Steve was most recently Vice President, Head of Biology, at Arrowhead Pharmaceuticals leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas and Astex Pharmaceuticals. Steve has authored over 80 publications in both peer-reviewed journals and books, and is an inventor on numerous U.S. and foreign patents and patent applications. Steve earned his undergraduate degree in genetics from the University of California, Berkeley, his Ph.D. in immunology and microbiology from the University of Miami’s Miller School of Medicine, and did his post-doctoral fellowship at the University of Virginia.
Chris Fuller, Ph.D.
Chris leads the informatics and software efforts at Caribou Biosciences and has a background managing diverse teams in developing instrumentation, medical devices, and microfluidic systems. He has held research and leadership positions in consulting, startup, and established company environments, including leading the development of the CellKey instrument for MDS Sciex from its inception through to product launch. Chris is an inventor of numerous patents and patent applications. He received his B.S. and M.S. degrees in Electrical Engineering from the Georgia Institute of Technology and a Ph.D. in Bioinformatics from the University of California, San Francisco.